Selvigaltin (GB1211), an orally obtainable small molecule galectin-three inhibitor developed like a treatment for liver fibrosis and cirrhosis, was evaluated to assess the influence of hepatic impairment on its pharmacokinetics and safety to address regulatory necessities. the RD team, and assessing the suggest with the fold-change for each variable in https://howardw222oal6.vblogetin.com/profile